This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2012 by Sheba Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Sheba Medical Center Identifier:
First received: December 12, 2012
Last updated: December 15, 2012
Last verified: December 2012
Pseudomonas is a common and virulent respiratory bacteria in patients with Cystic Fibrosis (CF). With time, the infection with Pseudomonas becomes chronic and very difficult to eradicate. The standard treatment of chronic Pseudomonas infection is inhaled Tobramycin which is given every other month.. Inhalation of Tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. However, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. The effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.

Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Improvement in quality of life [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Difference in exacerbation events [ Time Frame: 1 year ]

    To be measured by:

    Worsening of CF symptoms such as coughing, sputum, deterioration in FEV1, all of which require hospitalization

Estimated Enrollment: 40
Study Start Date: January 2013
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
CF patients with chronic pseudomonas infection


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
CF patients with chronic pseudomonas infection

Inclusion Criteria:

  • Age 6 years and above, Chronic Pseudomonas infection

Exclusion Criteria:

  • Younger than 6 years; No chronic PSeudomonas infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01749644

Contact: Ori Sarouk, MD 97235302884

Safra Children's Hospital, Sheba Medical Center Not yet recruiting
Ramat Gan, Israel
Contact: Ifat Sarouk, MD    97235302884      
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Ori Efrati, MD Safra Children's hospital, National CF Center
Principal Investigator: Ifat Sarouk, MD Safra Children's Hospital, National CF center
  More Information

Responsible Party: Sheba Medical Center Identifier: NCT01749644     History of Changes
Other Study ID Numbers: SHEBA-12-9640-OE-CTIL
Study First Received: December 12, 2012
Last Updated: December 15, 2012

Keywords provided by Sheba Medical Center:
Cystic Fibrosis, Chronic Pseudomonas Infection, Inhaled Tobramycin

Additional relevant MeSH terms:
Respiratory Aspiration
Respiration Disorders
Respiratory Tract Diseases
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 19, 2017